Announcements
- Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events
- Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
- Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
- Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
- Iovance Biotherapeutics to Present at Upcoming Conferences
- Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
- Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
- Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
More ▼
Key statistics
On Friday, Iovance Biotherapeutics Inc (2LB:FRA) closed at 6.78, 118.28% above the 52 week low of 3.11 set on Oct 19, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.78 |
---|---|
High | 6.78 |
Low | 6.78 |
Bid | 6.67 |
Offer | 6.73 |
Previous close | 6.86 |
Average volume | 2.33k |
---|---|
Shares outstanding | 279.83m |
Free float | 259.05m |
P/E (TTM) | -- |
Market cap | 2.07bn USD |
EPS (TTM) | -1.82 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 07:03 BST.
More ▼